TABLE 3.
HPV prevalence in LA and RM HNC and OPC, and OPC fraction, per geographic region.
| HPV Prevalence in HNC | |||||||
|---|---|---|---|---|---|---|---|
| n studies | Mean | Median | Range (min, max) | NHNC pts enrolled | NHPV+ HNC pts | Pooled | |
| Northern America | 34 | 46.0% | 43.6% | 8.3%–100.0% | 1923 | 809 | 42.1% |
| Europe | 29 | 24.7% | 22.7% | 3.1%–75.9% | 2804 | 710 | 25.3% |
| Northern Europe | 5 | 31.9% | 20.7% | 11.5%–75.9% | 377 | 238 | 63.1% |
| Southern Europe | 4 | 23.2% | 26.6% | 3.3%–36.4% | 284 | 75 | 26.4% |
| Western Europe | 17 | 24.3% | 25.0% | 3.1%–47.6% | 1381 | 325 | 23.5% |
| Multiple European regions a | 3 | 17.2% | 13.3% | 6.8%–31.6% | 762 | 72 | 9.4% |
| Eastern Asia | 3 | 20.1% | 16.7% | 10.3%–33.3% | 121 | 19 | 15.7% |
| Multiple continents | 15 | 19.8% | 21.6% | 2.9%–30.4% | 4759 | 874 | 18.4% |
| OPC Fraction in HNC | |||||||
| n studies | Mean | Median | Range (min, max) | N HNC pts enrolled | N OPC pts enrolled | Pooled | |
| Northern America | 31 | 56.9% | 57.8% | 4.3%–100.0% | 1797 | 1051 | 58.5% |
| Europe | 24 | 53.7% | 51.9% | 15.4%–85.2% | 2462 | 1371 | 55.7% |
| Northern Europe | 5 | 41.7% | 33.3% | 15.4%–85.2% | 377 | 273 | 72.4% |
| Southern Europe | 4 | 47.8% | 45.6% | 23.0%–76.9% | 284 | 128 | 45.1% |
| Western Europe | 13 | 60.3% | 60.2% | 37.5%–80.0% | 1279 | 777 | 60.8% |
| Multiple European regions a | 2 | 52.1% | 52.1% | 35.8%–68.4% | 522 | 193 | 37.0% |
| Eastern Asia | 2 | 33.0% | 33.0% | 22.9%–43.1% | 106 | 36 | 34.0% |
| Multiple continents | 12 | 36.0% | 36.5% | 13.8%–58.5% | 3848 | 1446 | 37.6% |
| HPV Prevalence in OPC | |||||||
| n studies | Mean | Median | Range (min, max) | N OPC pts enrolled | N HPV+ OPC pts | Pooled | |
| Northern America | 25 | 70.0% | 75.0% | 21.4%–100.0% | 577 | 423 | 73.3% |
| Europe | 17 | 44.1% | 44.4% | 14.3%–89.1% | 829 | 426 | 51.4% |
| Northern Europe | 4 | 61.4% | 65.7% | 25.0%–89.1% | 264 | 230 | 87.1% |
| Southern Europe | 4 | 48.2% | 49.3% | 14.3%–79.7% | 128 | 75 | 58.6% |
| Western Europe | 7 | 35.3% | 35.7% | 20.0%–50.0% | 244 | 81 | 33.2% |
| Multiple European regions a | 2 | 32.5% | 32.5% | 18.9%–46.2% | 193 | 40 | 20.7% |
| Eastern Asia | 1 | NA | NA | NA | 25 | 6 | 24.0% |
| Multiple continents | 9 | 41.6% | 38.9% | 15.8%–59.2% | 1283 | 521 | 40.6% |
Abbreviations: HPV, human papilloma virus; HNC, head and neck cancer; N pts, number of patients; n, number of studies; NA, not applicable; OPC, oropharyngeal cancer.
a
The category of multiple European regions includes multi‐country studies conducted in Europe. These studies were conducted in Western, Central/Eastern, and Southern Europe for HNC, and Southern and Western Europe for OPC.